IRVINE, Calif.–(BUSINESS WIRE)– Masimo, een internationale innovator van niet-invasieve patiëntcontrole, heeft vandaag bekendgemaakt dat de afgezwaaide senator Tom Harkin is verkozen tot lid van zijn raad van bestuur. Harkin diende vijf termijnen als senator en was voorzitter van het Senaatscomité voor gezondheid, onderwijs, werk en pensioen (HELP).
Harkin trad in januari 2015 af als senator. Hij was acht jaar lang voorzitter van HELP. Uit hoofde van deze functie werkte hij aan waarborgen voor een gezonde economie, toegang tot kwaliteitsonderwijs en betaalbare, kwalitatief goede gezondheidszorg voor alle Amerikanen. Harkin gaf vorm aan het lemma voor preventie en welzijn van de nieuwe zorgwet, de Patient Protection and Affordable Care Act. Harkins bekendste verworvenheid was de Americans with Disabilities Act (ADA) die onder zijn leiding en door zijn steun in 1990 werd aangenomen onder president George H. W. Bush. Later stichtte hij het Clinical Trials Network, dat de effectiviteit van rehabilitatietherapieën voor mensen met een verlamming meet. Hij stelde ook de Christopher and Dana Reeve Act op, die in 2009 werd aangenomen. Voorafgaand aan zijn aftreden werkte Harkin nauw samen met president Barack Obama aan het opheffen van beperkingen op onderzoek met embryonale stamcellen.
Retired U.S. Senator Tom Harkin Joins Masimo’s Board of Directors
IRVINE, Calif.–(BUSINESS WIRE)– Masimo (NASDAQ: MASI), a global innovator of noninvasive patient monitoring technologies, announced today that retired Senator Tom Harkin, former five-term U.S. Senator and former Chairman of the Senate Health, Education, Labor and Pension (HELP) Committee, has been elected to Masimo’s Board of Directors.
Senator Harkin retired from the U.S. Senate in January 2015. Senator Harkin was chairman of the Senate HELP Committee for eight years. In that role, he worked to ensure the health of our economy, guarantee access to quality education, and provide affordable, quality health care for all Americans. Senator Harkin crafted the prevention and wellness title of the country’s new health reform bill, the Patient Protection and Affordable Care Act. Senator Harkin’s signature legislation achievement was leading the effort and sponsorship of the Americans with Disabilities Act (ADA) signed into law in 1990 by President George H.W. Bush. He later created the Clinical Trials Network to measure the effectiveness of rehabilitation therapies for those living with paralysis, and drafted the Christopher and Dana Reeve Act, passed in 2009. Prior to his retirement, Senator Harkin worked closely with President Obama to lift restrictions on embryonic stem cell research.
“For years, Tom has worked tirelessly to ensure that everyone has access to affordable, quality health care and those who are in need are not forgotten. We are honored to welcome Tom to the Board,” said Joe Kiani, Chairman and CEO of Masimo. “We believe his integrity, extensive experience and insight into our complex health system, along with his dedication and passion to help those in need will be extremely valuable to Masimo.”
“I’ve been very impressed with Masimo’s innovations and contributions to healthcare,” said Harkin. “I got to know Joe through his advocacy work to improve competition in healthcare, align misaligned incentives that impede patient care and the Patient Safety Movement. He has been steadfast in his commitment to improve our healthcare system through innovation and advocacy. I look forward to working with him and the rest of the board to help Masimo with its mission to improve patient care and reduce cost of care.”
Senator Harkin was first elected to the U.S. House of Representatives in 1974, and 10 years later, he was elected to US Senate. Senator Harkin was born in Cumming, Iowa, where he still resides with his wife Ruth. They have two daughters and three grandchildren.
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through-Motion and Low Perfusion ™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.
Irene Paigah, 858-859-7001